APLM Stock Forecast: Apollomics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$16
−6.92% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 9 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$48.7M
Ticker Nerd rank
9/ 100
Median analyst target
—
Analysts covering
—
Total return, dividends reinvested
1W
−12.1%
1M
−29.5%
YTD
−16.9%
1Y
+5.3%
From 52W high
−44.5%
From 52W low
+20.9%
$13
$28
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Apollomics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
9/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
63
Momentum
47
Accruals
35
Growth
25
Revisions
20
Value
17
Quality
12
Issuance
1

Volatility (63): The share price has been relatively steady.

Issuance (1): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

APLM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on APLM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25$30Jan 26Apr 26Jul 26Oct 26APLM

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
8 May 2024HC Wainwright & Co.MaintainsBuy$5.00 → $2.00
1 Apr 2024EF HuttonMaintainsBuy—
1 Apr 2024HC Wainwright & Co.MaintainsBuy—
20 Nov 2023HC Wainwright & Co.ReiteratesBuy—
3 Oct 2023HC Wainwright & Co.MaintainsBuy—
23 Aug 2023EF HuttonAssumesBuy$25
5 June 2023HC Wainwright & Co.ReiteratesBuy—
1 June 2023HC Wainwright & Co.InitiatesBuy—
25 May 2023EF HuttonAssumesBuy$25
25 Apr 2023EF HuttonInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

APLM appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

APLM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Apollomics, Inc. returned +5.3% against +6.9% for the S&P 500, dividends included.

APLM vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Jan 26Apr 26Jul 26Oct 26APLMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

APLM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
104.0×

Cheaper than 3% of US stocks

Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
−98.8%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−67.1%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Apollomics, Inc. has a market value of $48.7M and an enterprise value of $38.0M.

  • Shares outstanding: 2.1M.

  • Apollomics, Inc. employs 14 people.

market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

APLM and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
APLMApollomics, Inc.$48.7M9
RNXTRenovoRx, Inc.$45.5M34
HOWLWerewolf Therapeutics, Inc.$46.0M90
GANXGain Therapeutics, Inc.$44.5M32
MISTMilestone Pharmaceuticals, Inc.$46.2M29
TNXPTonix Pharmaceuticals Holding Corp.$46.2M22
ANVSAnnovis Bio, Inc.$44.1M16

Take a look at APLM’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Apollomics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about APLM

How does Ticker Nerd's model rank APLM?

As at 21 Nov 2026, Apollomics, Inc. ranks 9 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (63 of 100).

What is the APLM stock forecast for 2030?

No analyst covering Apollomics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APLM are extrapolating price history, which says nothing about the business.

How has APLM stock performed over the past year?

Apollomics, Inc. returned +5.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Apollomics, Inc. do?

Apollomics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oncology therapies for cancer treatment. The company’s current pipeline centers on targeted medicines and immuno-oncology approaches designed to address molecular drivers of disease and support use alongside other treatment options.

Company

About Apollomics, Inc.

Apollomics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oncology therapies for cancer treatment. The company’s current pipeline centers on targeted medicines and immuno-oncology approaches designed to address molecular drivers of disease and support use alongside other treatment options. Its lead programs include vebreltinib, an oral c-Met inhibitor being studied in solid tumors with MET dysregulation, and APL-102, an oral multi-kinase inhibitor in early-stage cancer development. Apollomics also evaluates therapies for difficult-to-treat cancers such as non-small cell lung cancer and acute myeloid leukemia. Based in Foster City, California, Apollomics operates as a specialized biotechnology company within the broader oncology drug-development market, where it contributes experimental therapies aimed at precision medicine and unmet medical needs.

CEO Mr. Hung-Wen Chen · 14 employees · United States · https://www.apollomicsinc.com